CTMX News

Continuing the recent trend, four out of five deals priced below the range. This week, five companies raised $765 million, pricing an average of 19% below their proposed midpoints. All four deals that priced below traded up, popping 10% on average and ending the week up 12%; the one that priced in its range dropped 6% in its first day and ended the week down...read more

CytomX Therapeutics, a preclinical biotech developing tumor-activated cancer immunotherapies, raised $80 million by offering 6.7 million shares at $12, below the range of $14 to $16. CytomX Therapeutics plans to list on the Nasdaq under the symbol CTMX. CytomX Therapeutics initially filed confidentially on 7/24/2015. BofA Merrill Lynch, Jefferies and Cowen & Company acted as...read more

As many as 11 companies could go public this week, including the year's largest IPO (Digicel) and the fastest-growing company (Pure Storage). Both have proposed market caps of more than $3.5 billion, while six others target valuations of $300 million or less. Last week, there were also 11 IPOs set to price, but ...read more

CytomX Therapeutics, a preclinical biotech developing tumor-activated cancer immunotherapies, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, CytomX would command a fully diluted market value of $585 million. Existing...read more